GLP2: an underestimated signal for improving glycaemic control and insulin sensitivity

J Endocrinol. 2016 May;229(2):R57-66. doi: 10.1530/JOE-16-0035. Epub 2016 Apr 5.

Abstract

Glucagon-like peptide 2 (GLP2) is a proglucagon-derived peptide produced by intestinal enteroendocrine L-cells and by a discrete population of neurons in the brainstem, which projects mainly to the hypothalamus. The main biological actions of GLP2 are related to the regulation of energy absorption and maintenance of mucosal morphology, function and integrity of the intestine; however, recent experimental data suggest that GLP2 exerts beneficial effects on glucose metabolism, especially in conditions related to increased uptake of energy, such as obesity, at least in the animal model. Indeed, mice lacking GLP2 receptor selectively in hypothalamic neurons that express proopiomelanocortin show impaired postprandial glucose tolerance and hepatic insulin resistance (by increased gluconeogenesis). Moreover, GLP2 acts as a beneficial factor for glucose metabolism in mice with high-fat diet-induced obesity. Thus, the aim of this review is to update and summarize current knowledge about the role of GLP2 in the control of glucose homeostasis and to discuss how this molecule could exert protective effects against the onset of related obesity type 2 diabetes.

Keywords: GLP2; insulin resistance; obesity; type 2 diabetes.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Blood Glucose / metabolism*
  • Diabetes Mellitus, Type 2 / etiology
  • Diabetes Mellitus, Type 2 / metabolism
  • Diabetes Mellitus, Type 2 / prevention & control
  • Diet, High-Fat / adverse effects
  • Glucagon-Like Peptide 2 / metabolism*
  • Homeostasis
  • Humans
  • Insulin Resistance / physiology*
  • Mice
  • Models, Biological
  • Obesity / etiology
  • Obesity / metabolism
  • Signal Transduction

Substances

  • Blood Glucose
  • Glucagon-Like Peptide 2